Ferroptosis Induced by the AR-SREBP1-FASN Axis in Prostate Cancer
DOI:
https://doi.org/10.54097/w5eppe64Keywords:
Prostate Cancer; AR-SREBP1-FASN axis; lipid synthesis; Ferroptosis.Abstract
Prostate cancer is one of the most common malignant tumors in men. Although traditional endocrine treatments such as androgen deprivation therapy are effective in the early stage, the emergence of castration-resistant prostate cancer (CRPC) has posed a severe challenge to clinical practice. Studies have shown that prostate cancer has a unique lipid metabolism dependence, and ferroptosis, as a novel type of programmed cell death, is closely related to the lipid metabolism state of tumors, providing a new research perspective for breaking through the resistance dilemma. This article focuses on the role of the AR-SREBP1-FASN axis in the lipid metabolism reorganization and ferroptosis regulation of prostate cancer, analyzes the molecular mechanism by which androgen receptor regulates SREBP1 through transcription and activates FASN to mediate de novo synthesis of fatty acids and triglycerides, discusses the pathological significance of this pathway, and summarizes the synergistic treatment strategy of second-generation anti-androgen drugs combined with ferroptosis inducers and their potential value in reversing resistance. The analysis indicates that targeting the AR-SREBP1-FASN axis to break the lipid metabolism defense barrier is expected to provide a new therapeutic breakthrough for CRPC patients. However, the dynamic changes characteristics of this pathway in different disease stages of the human body are still unclear, and the clinical translation of specific small molecule inhibitors targeting SREBP1 or FASN still faces many obstacles, which are the directions for future research.
Downloads
References
[1] Freddie Bray, Mathieu Laversanne. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 2024, 74(3). DOI: https://doi.org/10.3322/caac.21834
[2] Rodrick Babakhanlou, Krisstina Gowin. The impact of diet and nutrition on prostate cancer – food for thought. Current Oncology Reports, 2025, 27(3). DOI: https://doi.org/10.1007/s11912-025-01641-x
[3] Mohler J L, Antonarakis E S, Armstrong A J, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network, 2019, 17(5): 479–505. DOI: https://doi.org/10.6004/jnccn.2019.0023
[4] Green S M, Mostaghel E A, Nelson P S. Androgen action and metabolism in prostate cancer. Molecular and Cellular Endocrinology, 2012, 360(1–2). DOI: https://doi.org/10.1016/j.mce.2011.09.046
[5] Yuan X, Cai C, Chen S, et al. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene, 2014, 33(22). DOI: https://doi.org/10.1038/onc.2013.235
[6] Romo-Perez A, Dueñas-González A, Chávez-Blanco A D, et al. PaSTe: blockade of the lipid phenotype of prostate cancer as metabolic therapy – a theoretical proposal. Current Medicinal Chemistry, 2024, 31(22). DOI: https://doi.org/10.2174/0929867330666230607104441
[7] Hsieh P F, Jiang W P, Huang S Y, et al. Emerging therapeutic activity of Davallia formosana on prostate cancer cells through coordinated blockade of lipogenesis and androgen receptor expression. Cancers, 2020, 12(4): 914. DOI: https://doi.org/10.3390/cancers12040914
[8] Ghoochani A, Hsu E, Aslan M, et al. Ferroptosis inducers are a novel therapeutic approach for advanced prostate cancer. Cancer Research, 2021, 81(6). DOI: https://doi.org/10.1158/0008-5472.CAN-20-3477
[9] Li B, Cheng B, Huang H, et al. Darolutamide-mediated phospholipid remodeling induces ferroptosis through the SREBP1–FASN axis in prostate cancer. International Journal of Biological Sciences, 2024, 20(12): 4635–4653. DOI: https://doi.org/10.7150/ijbs.101039
[10] Caspar-Bauguil S, Kolditz C I, Lefort C, et al. Fatty acids from fat cell lipolysis do not activate an inflammatory response but are stored as triacylglycerols in adipose tissue macrophages. Diabetologia, 2015, 58(11): 2627–2636. DOI: https://doi.org/10.1007/s00125-015-3719-0
[11] Zhang Y, Xin L, Xiang M, et al. The molecular mechanisms of ferroptosis and its role in cardiovascular disease. Biomedicine & Pharmacotherapy, 2022, 145: 112423. DOI: https://doi.org/10.1016/j.biopha.2021.112423
[12] Cai T, Song X, Xu X, et al. Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota. Frontiers in Cellular and Infection Microbiology, 2024, 14: 1323261. DOI: https://doi.org/10.3389/fcimb.2024.1323261
[13] Wei J T, Ma Z Y, Cao J, et al. Research progress of traditional Chinese medicine regulating ferroptosis in testicular spermatogenic epithelial injury. Chinese Journal of Andrology, 2024, 30(5): 450–455.
[14] Luo M, Yan J, Hu X, et al. Targeting lipid metabolism for ferroptotic cancer therapy. Apoptosis, 2023, 28(1–2): 81–107. DOI: https://doi.org/10.1007/s10495-022-01795-0
[15] Wang Y M, Qian R, Xie X H, et al. Mechanistic study on Wa medicine Niang-Mu-Liang medicinal liquor mitigating diabetes mellitus erectile dysfunction in rats by inhibiting ferroptosis. Integrative Medicine Discovery, 2024, 8(10): 1–5. DOI: https://doi.org/10.53388/IMD202408010
[16] Li X X, Wang B, Wang J S, et al. Role of lipid metabolism disorder–ferroptosis axis in diabetic erectile dysfunction: research progress. China Sexual Science, 2026, 35(4): 1–6.
[17] Yang Y, Liu T, Hu C, et al. Ferroptosis inducer crastin downregulates androgen receptor and its splice variants in castration-resistant prostate cancer. Oncology Reports, 2021, 45(4): 25. DOI: https://doi.org/10.3892/or.2021.7976
[18] Qin Z, Ou S, Xu L, et al. Design and synthesis of isothiocyanate-containing hybrid androgen receptor antagonist to downregulate androgen receptor and induce ferroptosis in glutathione-deficient prostate cancer cells. Chemical Biology & Drug Design, 2021, 97(5): 1059–1078. DOI: https://doi.org/10.1111/cbdd.13826
[19] Ji F H, Qian Y H, Guo X C, et al. Targeting RPS6KC1 to overcome enzalutamide resistance in prostate cancer. Biomarker Research, 2025, 13(1): 109. DOI: https://doi.org/10.1186/s40364-025-00822-x
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

